Barnes Group (B)
(Delayed Data from NYSE)
$37.74 USD
-0.20 (-0.53%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $37.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
B 37.74 -0.20(-0.53%)
Will B be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for B based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for B
Why Barnes Group (B) International Revenue Trends Deserve Your Attention
Barnes Group (B) Q2 Earnings Miss Estimates, Sales Rise Y/Y
B: What are Zacks experts saying now?
Zacks Private Portfolio Services
Barnes Group (B) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Barnes Group (B) Misses Q2 Earnings and Revenue Estimates
Crane (CR) Earnings Expected to Grow: Should You Buy?
Other News for B
ETQ Expands the Capabilities of ETQ Reliance QMS; Launches Inspection Management Application to Enable Faster, More Efficient Quality Inspections
Crawford & Company Reports 2024 Second Quarter Results
Global Quality in Manufacturing Survey from ETQ Reveals Dramatic Rise in Product Recalls
Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024
Long-term lecanemab data show increased patient benefit with maintained safety profile